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Abstract
Major depressive disorder (MDD) and generalized anxiety disorder (GAD) are severe and difficult-to-treat psychiatric ill-
nesses with high rates of comorbidity. Although both disorders are treated with serotonergic based psychotropic agents, little 
is known on the influence of the serotonergic neurotransmitter system on the occurrence of comorbid GAD when clinically 
depressed. To investigate this poorly understood clinical question, we examined the involvement of frontolimbic post-synaptic 
5-HT2A receptors in 20 medication-resistant depressed (MRD) patients with half of them diagnosed with comorbid GAD 
with 123I-5-I-R91150 SPECT. To explore whether 5-HT2A receptor-binding indices (BI) associated with comorbid GAD 
could be related to distinct psychopathological symptoms, all were assessed with the symptom Checklist-90-Revised (SCL-
90-R). MRD patients with comorbid GAD displayed significantly higher 5-HT2A receptor BI in the hippocampal–amygdala 
complex, compared to MRD patients without GAD. Correlation analyses revealed that the 5-HT2A receptor BI in these 
areas were significantly related to the SCL-90-R subscale hostility (HOS), especially for those MRD patients with comorbid 
GAD. Comorbid MRD-GAD may be characterized with increased hippocampal–amygdala 5-HT2A receptor BI which could 
represent enhanced levels in hostility in such kinds of patients. Adapted psychotherapeutic interventions may be warranted.
Keywords Major depressive disorder · Generalized anxiety disorder · Comorbidity · R91150 SPECT · serotonin 5-HT2A 
receptor
Introduction
Major depressive disorder (MDD) and generalized anxiety 
disorder (GAD) are widespread mental health problems and 
both illnesses are associated with high recurrence, comor-
bidity, and they prove to be difficult to treat, so treatment 
resistance is not uncommon [1, 2]. Pharmacologically man-
aged very similarly with serotonergic based antidepressants 
[3], it remains, however, unclear how the serotonergic sys-
tem is involved in the comorbid occurrence of GAD in the 
depressed state. Better neurobiological insights on the pres-
ence of comorbid GAD in MDD could be of considerable 
interest to fine-tune treatment algorithms in this difficult-to-
treat group and certainly in the medication-resistant state.
One possible target for investigation could be the G-pro-
tein coupled post-synaptic 5-HT2 receptor, which have 
been found to be involved in the pathophysiology of mood 
and anxiety disorders, suicide ideation, and MDD treat-
ment (non)response [4, 5]. Animal and human studies have 
shown that the 5-HT2A receptor is implicated in the context 
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of anxiety-related behaviors and MDD (see review by [6]). 
In addition, 5-HT2A receptor dysfunctions of frontolimbic 
processes are often observed in both GAD [7, 8] and MDD 
patients [9]. Indeed, functional brain-imaging studies in 
MDD, as well as in GAD, have also demonstrated deregu-
lated neuronal processing in the frontolimbic areas resulting 
in enhanced stress sensitivity disturbed emotion regulation 
processes, rumination, and worrying [10–12].
Recently, more attention has been given to the involve-
ment of ‘hostility’ and ‘anger’ in the depressed state [13, 
14], which refers to an emotional state varying from mild 
annoyance to rage [15]. Moreover, elevated levels of mul-
tiple dimensions of anger characterize individuals who 
meet diagnostic criteria for GAD [16]. Here intolerance 
of uncertainty could be a critical construct underlying the 
pathophysiology of GAD, and maladaptive behavioral and 
cognitive reactivity (e.g., biased contextual interpretations of 
the situation, poor decision-making) may not only increase 
worry and anxiety [17], but intolerance of uncertainty may 
also mediate the relationship between GAD symptoms and 
anger [18]. There is some evidence that supports positive 
cortical 5-HT2A receptor involvement in aggression, anger, 
and impulsivity [19]. Surprisingly, no studies have inves-
tigated serotonergic differences of comorbid GAD in the 
treatment-resistant depressed (MRD) state.
Consequently, we collected 20 antidepressant-free (uni-
polar) melancholic MRD patients (10 with current comor-
bid GAD) documented to be resistant to several pharmaco-
logical interventions, and to examine the influence of the 
5-HT2A receptor, we used SPECT and 4-amino-N-[1-[3-
(4-fluorophenoxy) propyl]-4-methyl-4-piperidinyl]-5-iodo-
2-methoxybenzamide (123I-5-I-R91150) as the radioligand 
[20] focusing on the frontolimbic areas. We also assessed 
the symptom Checklist-90-R (SCL-90-R [21]) to further 
investigate the relationship between SCL-90-R subscales 
(including a range of psychological measures, besides 
depression and anxiety, cognitive and conative symptoms 
such as hostility) and the 5-HT2A receptor BI, to enlarge our 
insights on the nature of the serotonergic involvement in the 
co-occurrence of GAD in patients diagnosed with MRD.
Although primary diagnosis was MRD for all patients, 
we hypothesized that MRD patients with comorbid GAD 
would display increased frontolimbic 5-HT2A binding BI 
when compared to those without the GAD comorbidity. 
Although we explored whether any of the SCL-90-R sub-
scale scores could be related to distinct 5-HT2A receptor BI 
between MRD patients with or without comorbid GAD, we 
expected that higher anxiety and the hostility subscale scores 
would be related to frontolimbic 5-HT2A binding BI.
Methods
Participants
In accordance with the guidelines laid down in the dec-
laration of Helsinki (2004) this study was approved by 
the Ethical Board of the University Hospital of the Vrije 
Universiteit Brussel. All patients gave informed consent 
to participate in the study and for publication. Twenty 
MRD patients (female: male = 13:7; age = 45.70 years, 
SD = 9.52) were included using the Dutch version of the 
Mini-International Neuropsychiatric Interview (M.I.N.I., 
edition 5.0.0 based on DSM-IV [22]), and all were diag-
nosed with unipolar melancholic MDD. Depression 
severity was assessed with the Beck Depression Inven-
tory (BDI-II-NL [23]). Ten patients (50% of the sample) 
were diagnosed with comorbid GAD. Comorbid psycho-
sis, bipolarity, and substance abuse/dependence were 
exclusion criteria. Since increased 5-HT2(A) receptor BI 
are reported in suicide victims [4], suicidal attempts dur-
ing the current depressive episode were considered as 
an exclusion criterion. According to the Thase and Rush 
criteria [24], patients were considered at least stage III 
treatment resistant: all had at least a minimum of two 
unsuccessful treatment trials with SSRI/NSRI and one 
failed clinical trial with a TCA. After a washout period, 
all patients were free from antidepressant, neuroleptics and 
mood stabilizers for at least two weeks before scanning. 
Only benzodiazepines taken on steady dose were allowed. 
This study was part of a larger investigation examining 
brain 5-HT2A receptor BI in medication-resistant depres-
sion. Given our recent focus on comorbidity in treatment-
resistant depression and GAD [25], we re-examined our 
initial cohort of 21 MRD patients used in an rTMS treat-
ment study [26]. For this study, only the baseline scans 
were included, before patients underwent the rTMS treat-
ment. Detected retrospectively, one male patient (38 years) 
diagnosed with MRD and comorbid GAD had an addi-
tional opioid addiction (paracetamol codeine for diffuse 
pain symptoms). Since opioids can increase intrasynaptic 
levels of serotonin [27], this patient was not included in 
the current study, nor in another study examining the char-
acterization of 5-HT2A receptor BI in MRD compared to 
age- and gender-matched drug-naive first episode MDD 
patients [28].
SCL‑90‑R
All patients were assessed with the Dutch version of the 
Symptom Checklist-90-R (SCL-90-R [21]). This 90-item 
self-report symptom inventory is designed to reflect 
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psychological symptom patterns of psychiatric and medi-
cal patients [29]. On a five-point Likert scale, participants 
rate the degree to which they have experienced symptoms 
during the past week. The symptom dimensions in the 
Dutch version are labeled as somatization (SOM), insuf-
ficiency in thought and behavior (IN), interpersonal sensi-
tivity (SEN), depression (DEP), anxiety (ANX), hostility 
(HOS), agoraphobia (AGO), sleeping problems (SLA), 
and rest symptoms not otherwise specified (REST). The 
mean value of all separate items is referred to as the Global 
Severity Index (GSI), an estimate of general psychological 
distress in psychiatric populations. Given that we were 
primarily interested in the first eight SCL-90-R subscales 
(and not the non-specified rest category), we only focused 
on SOM, IN, SEN, DEP, ANX, HOS, AGO, and SLA.
SPECT brain imaging
Static SPECT-imaging was performed with a Siemens Mul-
tiSPECT triple-headed gamma camera, equipped with par-
allel-hole medium-energy collimators. For thyroid blockage 
all patients received oral Lugol’s solution containing 400 mg 
of potassium iodide 15 min prior to injection of an average 
dose of 150 MBq 123I-5-I-R91150. SPECT acquisition was 
performed at a minimum of 120 min after administration of 
the tracer. Data were collected from 96 angular positions 
over 360° in a 128 × 128 matrix, with a total acquisition time 
of 32 min. Reconstruction of the acquired projection images 
was performed using an iterative reconstruction algorithm 
(Ordered Subset Expectation Maximization, OSEM, 8 
iterations, 8 subsets) and filtered with a 3D Gaussian using 
15 mm full width at half-maximum.
SPECT scans were automatically co-registered to a 
template image placed in a predefined stereotactic (image) 
space (BRASS; Nuclear Diagnostics Ltd., Sweden) (See also 
[30]). The sequential acquisition of transmission and emis-
sion images was further used to anatomically standardize the 
emission image using the same linear parameters as those 
used for the transmission image [31]. All images were visu-
ally double-checked to ensure correct anatomical positioning 
of the predefined VOIs [32].
Radioactivity estimates in the volumes of interest (VOI) 
were assumed to represent total ligand binding (specific plus 
nonspecific binding plus free ligand) [32]. Since very few 
5-HT2A receptors are present in the cerebellum, this region 
was chosen to represent nonspecific activity [20]. Calcula-
tion of relative indices of specific BI was performed by VOI 
normalization to the activity per volume element in the cer-
ebellum. Under these pseudo-equilibrium circumstances, BI 
is directly related to the in vivo receptor density (Bmax) and 
affinity (Kd). BI was defined as (target activity-background 
activity in the brain)/(background activity) which was 
operationally estimated as (counts/pixel in VOI-counts/pixel 
in the cerebellum)/(counts/pixel in the cerebellum) [31].
Given the relatively small study sample, for the analy-
sis we limited our number of VOIs to six: the brainstem, 
the dorsolateral prefrontal cortex (left + right DLPFC), 
orbitofrontal cortex (left + right OFC), ventrolateral pre-
frontal cortex (left + right VLPFC), anterior cingulate cor-
tex (left + right ACC), hippocampal–amygdala complex 
(left + right HippAM).
Statistical methods
All statistical analyses were performed with SPSS 25 (Statis-
tical Package for the Social Sciences, IBM, Chicago, USA). 
Where necessary, we applied the Greenhouse–Geisser cor-
rection to ensure the assumption of sphericity. The signifi-
cance level was set at p < 0.05, two-tailed, except for the 
SCL-90-R. Since the SCL-90-R was introduced for explora-
tory purposes and given that we were primarily interested in 
the first eight subscales, labeled SOM, IN, SEN, DEP, ANX, 
HOS, AGO, and SLA, for these eight subscale analyses with 
VOI 5-HT2A receptor-binding indices, here the p value, two-
tailed was Bonferroni corrected for the number of significant 
VOIs derived and eight subscales, was set at p < 0.00625, 
two-tailed (Bonferroni correction).
Behavioral analysis
Concerning the behavioral outcome results, we compared 
demographics and SCL-90-R questionnaire scores between 
MRD patients with and without comorbid GAD with X2 or 
t tests. See for details Table 1.
SPECT analysis
To test our hypothesis on 5-HT2A receptor BI differences 
between depressed patients with and without comorbid 
GAD, first, in a MANCOVA analysis the six VOIs were 
analyzed as multiple dependent variables and MRD group 
(GAD versus no GAD) was the fixed between subjects’ 
factor. Given that age-dependent reductions in 5-HT2A 
receptor-binding indices have consistently been reported 
[33, 34], we added age as covariate. Significant outcomes 
of the omnibus MANCOVA were followed up by univari-
ate analyses. Second, to control whether 5-HT2A receptor 
BI in these significant VOIs could be influenced by the 
individual daily dose intake of benzodiazepines (mg/day), 
the duration of the current depressive episode (years), 
suicide risk (MINI), or the individual depression sever-
ity scores (BDI-II), we performed an exploratory (par-
tial) correlation analysis (corrected for age) for the entire 
sample and for each MRD group (GAD versus no GAD) 
separately. Third, to evaluate whether one of the eight 
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symptom dimensions of the Dutch version of the SCL-
90-R was related to any of the significant VOI 5-HT2A 
receptor BI, again we performed an (partial) correlation 
analysis (corrected for age) between the significant VOIs 
and the eight SCL-90-R subscales for each MRD group 




MRD patients with (n = 10) or without GAD (n = 10) were 
not significantly different in age, gender distribution, ben-
zodiazepine use, depression severity, or current episode 
duration. See Table 1. Of note, for one patient (in the MRD 
group with comorbid GAD), the SCL-90-R questionnaire 
went missing, so to evaluate the effects of SCL-90-R sub-
scales only 19 patients were included. Here, we found that 
MRD patients with GAD scored significantly higher on 
insufficiency in thought and behavior (IN: p < 0.009) and 
nearly reached significance on Hostility (HOS; p = 0.052).
Table 1  Demographics
Data are presented as ratio, means and standard deviations
MDD major depressive disorder, GAD generalized anxiety disorder, BDI–II 21-item Beck Depression Inventory, F female, M male. Significance 
set at p < 0.05, two-tailed. Somatization (SOM), insufficiency in thought and behavior (IN), interpersonal sensitivity (SEN), depression (DEP), 
anxiety (ANX), hostility (HOS), agoraphobia (AGO), sleeping problems (SLA), and rest symptoms not otherwise specified (REST), Global 
Severity Index (GSI)
*In medians and interquartile ranges
All MRD patients Without GAD With GAD X2 or T tests p value
Gender (F:M) 13:7 6:4 7:3 0.22 0.64
Age 45.70 (9.52) 49.40 (10.41) 42.00 (7.26) 1.85 0.08
BDI-II 33.30 (11.17) 32.00 (11.95) 34.60 (10.80) 0.51 0.62
Depression episode duration (years) 4.38 (3.49) 3.35 (2.00) 5.40 (4.41) 1.34 0.20
Benzodiazepines (mg/day) 12.30 (23.41) 16.00 (28.75) 8.60 (17.31) 0.70 0.50
Suicide risk (MINI)* 1.00 (2.00) 0.50 (1.25) 1.00 (1.25) 2.10 0.18
SCL-90
 Subscales
  ANX 28.68 (7.54) 26.60 (6.29) 31.00 (8.47) 1.29 0.21
  AGO 16.47 (7.19) 13.80 (4.16) 19.44 (8.83) 1.75 0.11
  DEP 58.21 (13.46) 54.10 (14.72) 62.78 (10.93) 1.45 0.18
  SOM 33.74 (9.13) 31.30 (8.10) 36.44 (9.91) 1.24 0.23
  IN 28.84 (7.49) 24.80 (4.02) 33.33 (8.06) 2.97 < 0.01
  SEN 44.47 (14.91) 39.80 (12.48) 49.67 (16.35) 1.49 0.16
  HOS 11.42 (4.30) 9.50 (2.17) 13.56 (5.15) 2.09 0.05
  SLA 9.58 (3.90) 9.10 (3.45) 10.11 (4.48) 0.56 0.59
  REST 20.74 (4.93) 19.40 (4.88) 22.22 (4.82) 1.27 0.22
   GSI 252.16 (59.91) 228.40 (46.86) 278.56 (64.15) 1.96 0.07
Fig. 1  Sagittal glass brain view depicting the predefined volumes of 
interest (VOIs). The selected VOIS include brainstem, the dorsolat-
eral prefrontal cortex (DLPFC), the ventrolateral prefrontal cortex 
(VLPFC), the orbital prefrontal cortex (OFC), the anterior cingulate 
cortex (ACC), and the hippocampal–amygdala complex (HippAM)
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Brain imaging
First, the MANCOVA analysis, with the different corti-
cal VOIs (DLPFC, VMPFC, OFC, ACC, HippAM, and 
brainstem) as dependent variables, MRD group (GAD ver-
sus no GAD) as the between group fixed factor, and age 
as covariate, revealed a significant main effect of group 
[Wilks’ Lambda: F(6,12) = 3.48, p = 0.03, ηp2 = 0.64], and 
age [Wilks’ Lambda: F(6,12) = 3.03, p = 0.048, ηp2 = 0.60]. 
The individual univariate tests showed no significant age 
influences on 5-HT2A receptor BI, although only for the 
hippocampal–amygdala complex this nearly reached signifi-
cance [F(1,17) = 4.35, p = 0.052, ηp2 = 0.20]. The univariate 
analysis for the other VOIs were not significant (p’s > 0.05). 
Furthermore, only for the hippocampal–amygdala com-
plex, the individual univariate analysis showed a significant 
MRD group difference with a significant higher the 5-HT2A 
receptor BI in patients with comorbid GAD (mean = 301.48, 
sd = 136.64) compared to those without comorbid GAD 
(mean = 232.62, sd = 68.80) [F(1,17) = 5.08, p = 0.038, 
ηp2 = 0.23]. The other univariate analysis evaluating the other 
VOIs were not significant (p’s > 0.05). See also Table 2.
Second, partial correlation analysis (controlled for age) 
showed no significant association between HippAM 5-HT2A 
receptor BI and the use of benzodiazepines, depression 
severity, suicide risk, and the duration of the current depres-
sive episode for the entire sample, as well for the two groups 
(GAD vs. no GAD) separately (p’s > 0.01).
Third, because group differences were found to be signifi-
cant only for the HippAM VOI, for the (partial) correlation 
analysis with the SCL-90-R subscales, here, the p value was 
set at p < 0.00625, two-tailed (Bonferroni correction for eight 
SCL-90-R subscales). To evaluate whether any SCL-90-R 
questionnaire scales were associated with HippAM 5-HT2A 
receptor BI (mean = 266.82, sd = 114.09), the partial corre-
lation analysis (controlled for age: mean = 45.74, sd = 9.78) 
including all MRD patients showed a nearly significant 
positive correlation with the SCL-90-R subscale HOS 
only [(mean = 11.42, sd = 4.30), r(16) = 0.64, p = 0.007]. 
The results of the zero order correlation showed that there 
was a significant positive correlation between the HippAM 
5-HT2A receptor BI and hostility (HOS) only, r(17) = 0.59, 
p = 0.004, indicating that controlling for age had little effect 
on the strength of the relationship between the two vari-
ables. Separate explorative correlation analyses (not Bonfer-
roni corrected) were separately performed in MRD patients 
with GAD and without GAD to further investigate whether 
the HippAM 5-HT2A receptor BI and HOS correlation were 
any different between the two groups. Pearson partial cor-
relation analysis showed that there was no significant cor-
relation between both variables [r(8) = − 0.27, p = 0.23] in 
MRD patients without comorbid GAD. However, in MRD 
patients diagnosed with comorbid GAD, Pearson partial 
correlation analysis revealed a positive correlation between 
HippAM 5-HT2A receptor BI and the individual HOS scores 
[r(7) = 0.71, p = 0.02]. See also Fig. 2. In addition, to assess 
the significance of the difference between the two correlation 
coefficients using the Fisher r-to-z transformation, which 
showed a significant difference (z = − 2.18, p = 0.03).
Finally, given the relatively small sample size and the 
potential influence of age differences between the two 
groups, as an additional manipulation check, we removed the 
oldest patient (female, 61 years, no GAD), and repeated all 
analyses. Besides that indeed there were no significant age 
differences between the two groups [t(17) = 1.52, p = 0.15], 
this did not affect any of the former outcome results, indicat-
ing that age was not a major influencer between the group 
analyses.
Table 2  VOI 5-HT2A receptor 
BI
Univariate analysis
VOIs Volumes of interest, DLPFC the brainstem, the dorsolateral prefrontal cortex, VLPFC ventrolateral 
prefrontal cortex, OFC orbital prefrontal cortex, ACC anterior cingulate cortex, HippAM hippocampal–
amygdala complex
All p values are age corrected
5-HT2A receptor BI All MRD patients Without GAD With GAD F test p value
VOIs
 DLPFC 104.50 (6.50) 104.69 (7.15) 104.32 (6.17) 0.05 0.83
 VLPFC 107.71 (4.31) 108.05 (4.56) 107.38 (4.27) 0.34 0.57
 OFC 107.85 (10.32) 107.33 (9.63) 108.38 (11.47) 0.35 0.56
 ACC 106.68 (5.97) 107.35 (5.74) 106.01 (6.42) < 0.01 0.97
 HippAM 267.05 (111.05) 232.62 (68.80) 301.48 (136.64) 5.08 0.038
 Brainstem 125.26 (16.27) 126.23 (17.98) 124.29 (15.27) 0.02 0.88
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Discussion
MRD patients with a comorbid diagnosis of GAD scored 
higher on insufficiency in thought and behavior (IN), and 
on hostility (HOS). Both behaviors have been reported when 
clinically depressed and/or when diagnosed with GAD [3, 
15]. Whereas the IN dimension focuses on feelings of per-
sonal inadequacy and inferiority in comparisons with oth-
ers—including self-deprecation, uneasiness, and discomfort 
during interpersonal interactions—higher scores on HOS 
indicates thoughts, feelings, or actions characteristic of the 
negative affect state of anger reflecting qualities such as 
aggression, irritability, rage and resentment [29]. Besides 
that, the demographics in both groups were similar (see 
Table 1), depression and anxiety SCL-90-R subscale scores 
did also not differ between the two groups, which suggests 
that the levels of depression and anxiety symptoms were 
not influenced by the occurrence of comorbid GAD in our 
MRD sample.
Concerning our SPECT results, the lack of frontal cor-
tical group 5-HT2A receptor BI differences in our sample 
indicates that serotonergic influences may not differ in MRD 
with or without comorbid GAD, suggesting no top–down 
cognitive different influences from the frontal cortical areas 
[5]. Of note, findings concerning the frontal cortical 5-HT2A 
receptor in the depressed state are not univocal, with some 
authors demonstrating 5-HT2A receptor increases, and oth-
ers demonstrating decreases, or no differences in receptor 
ligand binding at all [28]. On the other hand, the observed 
increased (hippocampal) amygdala 5-HT2A receptor BI 
agrees with its modulating capacity of anxiety-states and 
anxiety-related behavior and are probably modulated by 
GABAergic interneurons in the (basolateral) amygdalae 
[35]. Of interest, in patients with Urbach–Wiethe disease, 
displaying severe bilateral amygdala damage, this syndrome 
has been associated with decreases in amygdala 5-HT2A 
receptor density and related to decreased fear and anxiety 
behavioral manifestations [36]. In addition, because of its 
involvement in the hypothalamic–pituitary–adrenal (HPA)-
stress system, the role of the hippocampus in the glucocorti-
coid regulation of stress reactions is well known [37]. Here, 
the HPA-system is thought to be regulated by serotonin in 
hippocampal neurons [38, 39], and especially by hippocam-
pal 5-HT2A receptor activation [40].
It is of interest to note that in patients suffering from 
Borderline Personality Disorder—an emotional unstable 
and stress-sensitive personality disorder characterized 
amongst other symptoms with separation anxiety, anger 
and impulse control disturbances—only hippocampal 
5-HT2A receptor binding was increased, independent of 
depressed mood [41]. Our (partial) correlation analysis 
showed that increases in HippAM 5-HT2A receptor BI 
Fig. 2  Scatter plots between the individual scores on hostility (HOS) 
(x-axis) and Hippocampal amygdala 5-HT2A receptor BI complex 
(y-axis) for the entire medication-resistant depressed (MRD) sample 
(straight thin full line), and plotted separately for MRD patients with 
generalized anxiety disorder (GAD) (thick full line and full bullets) 
and without comorbid GAD (dashed thick line and open bullets). Of 
note, the lines representing the least-squares fit to the data are not 
corrected for age
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were related to higher scores on the SCL-90-R subscale 
score hostility (HOS) in the MRD state. Common with 
BPS symptoms, our exploratory partial correlation analy-
sis also showed that increased HippAM 5-HT2A receptor 
BI in relation to increased hostility could me especially 
apparent in MRD patients with comorbid GAD. In addi-
tion, GAD may lead to emotional dysregulation, including 
unsuppressed anger and low tolerance to frustration [42]. 
In addition, higher levels of anger and hostility contributed 
and predicted GAD symptom severity and elevated levels 
of multiple dimensions of anger characterized individuals 
who met the diagnostic criteria for GAD [16].
In preclinical studies, the involvement of the 5-HT2A 
receptor in anxious behavior has been observed in dogs 
[43], and disinhibited aggressive behavior associates 
with an increased cortical uptake of the 5-HT2A receptor 
radioligand 123I-5-IR91150 [44]. Of interest, successful 
SSRI treatment in impulsive-aggressive dogs downregu-
lated the cortical 5-HT2A receptor BI also in the temporal 
cortical areas, in canine species regarded as part of the 
hippocampal complex [45]. In depressed adolescents, a 
single dose of fluoxetine also immediately reduced neu-
ral amygdala–hippocampal activity in response to angry 
facial expressions [46]. Furthermore, among outpatients 
with MDD early clinical improvement in anger/hostil-
ity symptoms may predict response to antidepressant 
treatment with fluoxetine [47]. It may of interest to note 
that, although we focused on 5-HT2A receptor BI in the 
frontolimbic regions, with inclusion of the brainstem, 
the investigated VOIs are structurally connected to the 
medial forebrain bundle, primarily mediated by the dopa-
minergic system as being part of the reward pathway tar-
geting similar brain regions also selected for our current 
5-HT2A post-synaptic receptor study (MFB; [48]). In TRD 
patients, these (superolateral) MFB has been recently the 
target areas for deep-brain stimulation (DBS; [49, 50]) 
offering depressed patients unresponsive to several phar-
macotherapeutic interventions an option to relief their 
mental burden. It would be of interest to verify in future 
DBS studies in depression whether clinical improvement 
also differentially attenuates hostility thoughts and actions 
in TRD patients diagnosed with or without GAD.
Patients diagnosed with GAD tend to avoid intense nega-
tive emotions by engaging in worry or behavioral avoidance, 
which may lead to an increase in emotional distress [51], 
displaying an elevated intolerance of uncertainty (IU) and 
anger [52]. Importantly, individual and group psychothera-
peutic sessions targeting this IU construct in GAD patients 
may result not only in decreases in IU, but also on worrying 
and on angriness [18, 53]. One could speculate that MRD 
patients with comorbid GAD may benefit from such spe-
cific additional psychotherapeutic interventions, impacting 
elevated HippAM 5-HT2A receptor BI.
Besides the obvious limitation, the relatively small sam-
ple size, all interpretations should be limited to melancholic 
MRD patients. Since we have not contrasted our findings 
to a non-depressed group, a GAD group with no comor-
bid (treatment resistant) depressed episode, the absence of 
cortical group 5-HT2A receptor BI only implies that in the 
MRD cohort frontal 5-HT2A receptor densities are not sig-
nificantly different with co-occurrence of GAD, and that the 
hippocampal–amygdala serotonergic findings are specific for 
the comorbid existence of MRD and GAD. A healthy control 
group could also have been informative to examine whether 
5-HT2A receptor VOI-binding indices would be any different 
between the healthy and the depressed state, and to evalu-
ate whether in healthy samples hostility symptoms would 
also be related to higher HippAM 5-HT2A receptor densities. 
Although MDD was the primary diagnosis, it remains pos-
sible that for some the diagnoses of GAD preceded the MDD 
episode, and not vice versa (e.g., [54]). We used the MINI as 
a diagnostic tool, but the severity of GAD symptoms was not 
examined with disease specific questionnaires. The MINI 
does also not include any personality diagnostic measure-
ment. Although the amygdala and hippocampus may serve 
different neuronal and behavioral functions, the limited reso-
lution of the SPECT scan prohibited clear disentanglement 
of 5-HT2A receptor BI between the two anatomical structures 
[55]. Future PET ligand studies, more capable to delineate 
between hippocampus and amygdala could examine poten-
tial 5-HT2A receptor BI regional differences. Of note, given 
the sample size of only 20 MRD patients, due to potential 
insufficient statistical power, the negative findings of the 
other VOIs may be a false negative. Since left and right 
VOIs were pooled due to the relatively small sample size, 
we cannot comment on possible lateralization influences.
In conclusion, the increased hippocampal–amygdala 
5-HT2A receptor BI found in depressed patients documented 
to be resistant to several antidepressant interventions and 
with the comorbid diagnosis of generalized anxiety could 
represent a serotonergic biomarker for this comorbid occur-
rence. Furthermore, the enhanced levels in hostility related 
to hippocampal–amygdala 5-HT2A receptor BI in such kinds 
of patients displaying this comorbidity could indicate that 
adapted psychotherapeutic interventions may be warranted. 
It remains without saying that these preliminary findings 
should be replicated in larger clinical samples to substantiate 
our assumptions.
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